Clinical Trials Logo

Infection, Bacterial clinical trials

View clinical trials related to Infection, Bacterial.

Filter by:

NCT ID: NCT06379061 Recruiting - Clinical trials for Infection, Bacterial

Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts

Start date: June 12, 2024
Phase:
Study type: Observational

The purpose of the pivotal study is to collect blood specimens and clinical data from pediatric (>90 days old) and adult (≥18 years old) patients presenting with signs and symptoms suggestive of acute bacterial or viral infection. These samples will be used to establish the diagnostic performance of MeMed BV™ for differentiating bacterial from viral infection using method comparison and/or method concordance.

NCT ID: NCT06283433 Recruiting - Clinical trials for Infection, Bacterial

A Dried Blood Spot Sampling Method for Vancomycin and Creatinine Monitoring for OPAT

ADVANCEDOPAT
Start date: October 25, 2023
Phase: N/A
Study type: Interventional

The Outpatient Parenteral Antibiotic Therapy (OPAT) service consists of providing antimicrobial therapy through parenteral infusion without hospitalization. This service is provided to stable patients otherwise ready for hospital discharge. Generally, the clinical monitoring for this patient population is minimal. However, clinical monitoring of vancomycin, an antibiotic widely used during OPAT, can be intensive primarily due to therapeutic drug monitoring. To ensure optimal treatment and minimize nephrotoxicity and microbial resistance, TDM and monitoring of serum creatinine levels are crucial during vancomycin therapy. TDM of vancomycin with OPAT presents a challenge for patients who must frequently travel to blood sampling facilities or the hospital for measurements. An alternative sampling method for TDM is the dried blood spot (DBS) method, which involves collecting a small drop of capillary blood from a finger prick onto filter paper. By implementing the DBS sampling method, the amount of outpatient visits regarding vancomycin treatment in OPAT can be reduced. Furthermore, the addition of measuring a biochemical parameter, such as renal function with serum creatinine, could lead to even less outpatient visits during OPAT. To date, studies investigating the effectiveness of DBS sampling of vancomycin and creatinine in terms of reducing outpatient visits have not yet been conducted in the OPAT population.

NCT ID: NCT06220370 Not yet recruiting - Clinical trials for Infection, Bacterial

PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised.

PATH
Start date: March 1, 2024
Phase:
Study type: Observational

We seek to characterise the burden and outcomes of and understand the current experience of people who inject drugs admitted to hospital with invasive injecting-related infections, in order to implement and evaluate strategies to improve completion of therapy and reduce patient-directed discharges, with ultimate benefit to the patient and health service.

NCT ID: NCT06190548 Completed - Clinical trials for Infection, Bacterial

Clinical Outcomes of Hypervirulent Carbapenem-resistant Klebsiella Pneumoniae Infection

HVCRKP
Start date: July 1, 2019
Phase:
Study type: Observational

The goal of this observational study is to learn about the risk factors of mortality for CRKP infected patients, and to compare the clinical outcomes between hvCRKP infection and cCRKP infection. The main question it aims to answer is • Whether hypervirulence would add value to cCRKP infection and cause worse outcomes? Participants data will be collected through medical records.

NCT ID: NCT06178822 Recruiting - Sepsis Clinical Trials

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

BIOSEP
Start date: October 25, 2022
Phase:
Study type: Observational [Patient Registry]

Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.

NCT ID: NCT06166381 Not yet recruiting - Clinical trials for Infection, Bacterial

Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in ACL Reconstruction

Start date: January 25, 2024
Phase: N/A
Study type: Interventional

An anterior cruciate ligament (ACL) tear is one of the knee joint's most common soft tissue injuries [1]. It is frequently injured in non-contact and some contact competition sports and even during ordinary life activities. With an annual incidence of 68.6 per 100,000 person-years, ACL tears remain a common orthopedic injury [2]. Females are two to eight times more likely to develop ACL tears in sports compared to men who play the same particular sports [3]. Most highly demanding persons and those who develop frequent instability of their knee require reconstructive surgery on the ACL to prevent early degenerative changes in their knees. This is done by completely removing the torn or ruptured ACL and replacement with a piece of tendon or ligament (graft) [4]. Post-operative infection may occur in 0.14-2.6% of ACL reconstruction despite intravenous antibiotics prophylaxis [5,6]. The deep infection results in poor outcomes with pain, stiffness, arthrofibrosis, and articular cartilage degeneration [7,8]. Few studies reported improved outcomes of infection control when the autograft presoaked in vancomycin solution during the preparation process outside the body before being transferred to the knee of the patient [9-13]. Systematic reviews and meta-analysis showed that all the articles discussing the outcome of vancomycin presoaked autograft in ACL reconstruction surgery were case series, observational retrospective, prospective comparative, or case-control studies [14,15]. Randomized control trial (RCT) provides the strongest evidence among the primary research studies to confirm the effectiveness of a new method of treatment [16,17]. To date, there is no available RCT study in this field.

NCT ID: NCT06143657 Not yet recruiting - Clinical trials for Infection, Bacterial

Clinical Performance Evaluation of AI-Enabled Automated Gram Staining Device

Start date: January 10, 2024
Phase:
Study type: Observational

The investigators have developed an analysis AI for Gram staining. In this study, the investigators will compare the testing accuracy of automated Gram staining equipment with AI with the testing accuracy of laboratory technicians. Based on the results, the investigators will examine the possibility of clinical application of the automated Gram staining device.

NCT ID: NCT06126900 Recruiting - Clinical trials for Infection, Bacterial

Smartphone App-assisted Short-term Antibiotic Therapy

SMAPP
Start date: January 15, 2024
Phase: N/A
Study type: Interventional

Outpatients with short-term antibiotic treatment should start and finish the treatment according to medical advise that is, the intake pattern (named adherence) should be regular. The research question is: Can a smartphone-based program including intake reminder and two text messages improve adherence to a short-term antibiotic treatment in ambulatory setting? Participants will be asked to record every antibiotic intake in an app on their smartphone over the prescribed therapy duration and to note their symptoms once daily. One group will obtain reminder + text messages, and the control group will have no reminder + no text messages.

NCT ID: NCT06126263 Active, not recruiting - Clinical trials for Infection, Bacterial

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

iGASAntitox
Start date: January 1, 2023
Phase:
Study type: Observational

This study aims to emulate a hypothetical target pragmatic multi-center, non-blinded trial of adult inpatients in the PINC AITM dataset with B-lactam treated culture confirmed monomicrobial invasive Group A streptococcus (GAS) between the years 2015-2021

NCT ID: NCT06093269 Recruiting - Clinical trials for Infection, Bacterial

Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL)

CEFAZODIAL
Start date: November 20, 2023
Phase: Phase 4
Study type: Interventional

In chronic hemodialysis patients, bacteremia is most commonly caused by dialysis catheter infections. It is estimated that the vast majority (52-84%) of these infections are due to Gram-positive cocci, particularly Staphylococcus aureus (21-43%). Penicillin M (oxacillin and cloxacillin in France) is the reference beta-lactam for the treatment of invasive methicillin-sensitive S. aureus (MSSA) infections, but has not shown a prognostic benefit in large retrospective cohorts comparing penicillin M and cefazolin, at the expense of more frequent adverse events. Dosage in the chronic hemodialysis population is unclear because it is based on old studies.